ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.283,62
0,20%
S&P 500
5.297,10
-0,21%
US Dollar vs BRL
5,1303
0,00%
Bitcoin
65.228,63
-0,02%
Brent Oil
83,415
0,25%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Exelixis Inc (EXEL)

  7. Exelixis Inc (EXEL) Notícias

EXEL

Exelixis (EXEL)

Exelixis Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:EXEL
DataHoraFonteTítuloCódigoCompanhia
15/05/202420:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
13/05/202417:03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXELExelixis Inc
10/05/202417:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EXELExelixis Inc
08/05/202417:11Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:EXELExelixis Inc
07/05/202417:05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in MayNASDAQ:EXELExelixis Inc
30/04/202417:05Business WireExelixis Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:EXELExelixis Inc
16/04/202417:05Business WireExelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024NASDAQ:EXELExelixis Inc
27/02/202418:05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in MarchNASDAQ:EXELExelixis Inc
13/02/202411:19Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:EXELExelixis Inc
06/02/202418:49Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EXELExelixis Inc
06/02/202418:05Business WireExelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:EXELExelixis Inc
01/02/202418:05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in FebruaryNASDAQ:EXELExelixis Inc
25/01/202410:00Business WireExelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024NASDAQ:EXELExelixis Inc
23/01/202418:05Business WireExelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024NASDAQ:EXELExelixis Inc
22/01/202419:00Business WireOpdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell CarcinomaNASDAQ:EXELExelixis Inc
18/01/202418:05Business WireEuropean Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) TabletsNASDAQ:EXELExelixis Inc
09/01/202423:03Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
07/01/202418:00Business WireExelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024NASDAQ:EXELExelixis Inc
02/01/202418:05Business WireExelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024NASDAQ:EXELExelixis Inc
07/12/202318:05Business WireExelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023NASDAQ:EXELExelixis Inc
04/12/202310:02Business WireExelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck CancerNASDAQ:EXELExelixis Inc
04/12/202310:00Business WireExelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell CarcinomaNASDAQ:EXELExelixis Inc
21/11/202318:05Business WireExelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023NASDAQ:EXELExelixis Inc
10/11/202311:00Business WireExelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023NASDAQ:EXELExelixis Inc
01/11/202317:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EXELExelixis Inc
01/11/202317:05Business WireExelixis Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:EXELExelixis Inc
22/10/202303:30Business WireDetailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023NASDAQ:EXELExelixis Inc
18/10/202317:05Business WireExelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023NASDAQ:EXELExelixis Inc
12/09/202309:00Business WireExelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 InhibitorNASDAQ:EXELExelixis Inc
31/08/202317:05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in SeptemberNASDAQ:EXELExelixis Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:EXEL

Seu Histórico Recente

COIN
FUTRBTC
GATE
PSGETH
Paris Saint-Germain
NYSE
CLIA
Tidal Trust II
NASDAQ
XFINU
ExcelFin Acquisition
BIT
S29336
Societe Generale Effekten
BIT
S7LCOA
Societe Generale Effekten
COIN
SFMBTC
SafeMoon
LSE
47RM
Qnb Fin 33
NYSE
ACND.U
Ascendant Digital Acquis...
LSE
ZQ15
Citi Fun 24
BOV
D1EX34Q
Dexcom
BIT
S25012
SG ISSUER
BIT
UC7T4S
Unicredit Bank
LSE
PA34
Citi Fun 25
LSE
XW63
Citi Fun 25
BINA
VOXELBTC
VOXEL Token
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados